전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
lasofoxifene
lasofoxifeen
마지막 업데이트: 2014-11-21
사용 빈도: 6
품질:
fablyn lasofoxifene
fablyn lasofoxifen
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the active substance is lasofoxifene.
het werkzame bestanddeel is lasofoxifen.
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
lasofoxifene is extensively metabolized in humans.
lasofoxifen wordt uitgebreid gemetaboliseerd bij de mens.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
lasofoxifene has a half-life of approximately 6 days.
lasofoxifen heeft een halfwaardetijd van ongeveer 6 dagen.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
fablyn 500 microgram film-coated tablets lasofoxifene
fablyn 500 microgram filmomhulde tabletten lasofoxifen
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
lasofoxifene has the same effect as oestrogen in the bone.
lasoxifen heeft hetzelfde effect op de botten als oestrogeen.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
animal studies have shown excretion of lasofoxifene in milk.
studies bij dieren hebben uitscheiding in de moedermelk aangetoond.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
fablyn is a medicine that contains the active substance lasofoxifene.
fablyn is een geneesmiddel dat de werkzame stof lasofoxifen bevat.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the pharmacokinetics of lasofoxifene have not been evaluated in a paediatric population.
de farmacokinetiek van lasofoxifen is niet onderzocht bij kinderen .
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
there are no adequate data from the use of lasofoxifene in pregnant women.
er zijn niet genoeg gegevens over het gebruik van lasofoxifen bij zwangere vrouwen.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
lasofoxifene is highly bound to proteins in human plasma (>99%).
lasofoxifen wordt in menselijk plasma sterk aan eiwitten gebonden (>99%).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
patients with this medical history should have serum triglycerides monitored when taking lasofoxifene.
bij patiënten met deze medische geschiedenis moet tijdens het gebruik van lasofoxifen de serumtriglyceridenspiegel regelmatig gecontroleerd worden.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
less than 2% of the administered dose was recovered in the urine as unchanged lasofoxifene.
minder dan 2% van de toegediende dosis werd als onveranderde lasofoxifen aangetroffen in de urine.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
each film-coated tablet contains lasofoxifene tartrate, equivalent to 500 micrograms lasofoxifene.
elke filmomhulde tablet bevat lasofoxifentartraat, overeenkomend met 500 microgram lasofoxifen vrije base.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
warfarin - lasofoxifene had no effect on the pharmacokinetics of r- and s- warfarin.
warfarine - lasofoxifen had geen effect op de farmacokinetiek van r- en s-warfarine.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
steady-state pharmacokinetics of lasofoxifene are consistent with expectations from its single-dose pharmacokinetics.
de steady-state- farmacokinetiek van lasofoxifen is consistent met de verwachtingen op basis van de farmacokinetiek bij een eenmalige dosis.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
biotransformation and disposition of lasofoxifene in humans have been determined following oral administration of 14c-labeled lasofoxifene.
de biotransformatie en dispositie van lasofoxifen bij de mens is vastgesteld na orale toediening van met 14c gelabeld lasofoxifen.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the active substance in fablyn, lasofoxifene, is a selective oestrogen receptor modulator (serm).
de werkzame stof van fablyn, lasofoxifen, is een selectieve oestrogeenreceptormodulator (serm).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
the apparent volume of distribution (v/f) of lasofoxifene in postmenopausal women is approximately 1,350 l.
het schijnbare distributievolume (v/f) van lasofoxifen bij postmenopauzale vrouwen is ongeveer 1.350 l.
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질: